MediWound Ltd. - ADR

Name: MediWound Ltd. - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: MediWound Ltd. - ADR

Stock Card

$13.12

$0.42 (3.27%)

As on 27-Aug-2026 13:35EDT

Market cap

$171 Mln

Revenue (TTM)

$12 Mln

P/E Ratio

P/B Ratio

4.8

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

MediWound - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 12.72 High: 13.25

52 Week Range

Low: 12.63 High: 20.03

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.7 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-6.3
Debt to Equity

0
Book Value

$--
EPS

$-1.6
Face value

--
Shares outstanding

12,910,278

10 Years Aggregate

CFO

$-109.07 Mln

EBITDA

$-108.68 Mln

Net Profit

$-128.80 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
MediWound - ADR	-29.0	-7.8	-21.4	-22.1	14.1	-12.1	-13.3
BSE Sensex	-9.1	1.1	1.2	-4.8	5.8	6.6	10.7
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021	2020	2019
MediWound - ADR	3.7	-24.6	-18.3	-36.2	19.4	-23.6
S&P Small-Cap 600	4.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
MediWound - ADR	13.1	170.5	11.9	-20.2	-176.1	-50.9	--	4.8
Kamada - ADR	8.2	475.4	191.9	22.3	13.9	8.3	21.7	1.8
PolyPid (PYPD)	5.1	103.6	0.0	-31.5	--	-385.1	--	19.2

Shareholding Pattern

View Details

About MediWound - ADR

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The... company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. Read more

Chief Financial Officer

Ms. Hani Luxenburg
Chief Financial Officer

Ms. Hani Luxenburg
Headquarters

Yavne
Website

https://www.mediwound.com

FAQs for MediWound - ADR

What is the current share price of MediWound Ltd - ADR Today?

The share price of MediWound Ltd - ADR is $13.12 (NASDAQ) as of 27-Aug-2026 13:35 EDT. MediWound Ltd - ADR has given a return of 14.1% in the last 3 years.

What is the current PB & PE ratio of MediWound Ltd - ADR?

Since, TTM earnings of MediWound Ltd - ADR is negative, P/E ratio is not available.
The P/B ratio of MediWound Ltd - ADR is 4.77 times as on 21-Aug-2026, a 0 premium to its peers’ median range of 4.77 times.

PE & PB ratio at the end of financial year.